The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19
NCT ID: NCT04932876
Last Updated: 2021-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
100 participants
OBSERVATIONAL
2021-04-24
2023-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ANTI-SARS-CoV-2 SEROCONVERSIO IN IMMUNE-MEDIATED KIDNEY DISEASES
NCT06753942
Immune Response Following COVID-19 in Hemodialysis Patients
NCT05307601
Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
NCT04815850
Kidney Disease After COVID-19
NCT05328986
Early Renal Replacement Therapy in COVID 19 Patients With AKI Does it Improve the Outcome?
NCT05274685
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ESKD - HD
End Stage Kidney Disease on Long Term Dialysis
SARS - COV 2 VACCINE
Vaccination for SARS - COV 2
KTR
Kidney Transplant Recipient
SARS - COV 2 VACCINE
Vaccination for SARS - COV 2
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SARS - COV 2 VACCINE
Vaccination for SARS - COV 2
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Covid 19 vaccination
Exclusion Criteria
* recent infection
* chronic infection
* HBV, HCV, HIV
* Active malignancy
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Ioannina
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Evangelia Ntounousi
Assistant Professor Of Nephrology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Evangelia Ntounousi
Ioannina, Epirus, Greece
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RESCOMUOI82152
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.